Gemcitabine-Induced Hemolytic Uremic Syndrome: a Case Report
Open Access
- 17 December 1997
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 89 (24) , 1895-1896
- https://doi.org/10.1093/jnci/89.24.1895
Abstract
Hemolytic uremic syndrome (HUS) is a rare side effect of chemotherapeutic agents reported in patients treated with cisplatin and bleomycin ( 1 ) , mitomycin C ( 2 ) , and high-dose chemotherapy in general ( 3 ) . Gemcitabine is an effective drug for systemic therapy of non-smallcell lung cancer (NSCLC) ( 4 ) and has few, well-defined side effects ( 5 ) . One report ( 6 ) has been published about a mild HUS that appeared related to gemcitabine therapy. This report is to extend this observation in one patient who developed severe HUS in connection with the administration of gemcitabine therapy.Keywords
This publication has 3 references indexed in Scilit:
- Mitomycin-C Induced Hemolytic Uremic Syndrome: A Case Report and Literature ReviewJapanese Journal of Clinical Oncology, 1997
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- Hemolytic Uremic Syndrome Following Cisplatin, Bleomycin, and Vincristine ChemotherapyRenal Failure, 1989